Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity

Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system w...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Harshad Kapare [verfasserIn] Sarika Metkar [verfasserIn] Satish Shirolkar [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles

Übergeordnetes Werk:	In: Nanomedicine Research Journal - Iranian Society of Nanomedicine, 2018, 5(2020), 4, Seite 316-323
Übergeordnetes Werk:	volume:5 ; year:2020 ; number:4 ; pages:316-323

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.22034/nmrj.2020.04.002

Katalog-ID:	DOAJ065304969

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ065304969
003	DE-627
005	20230502132337.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.22034/nmrj.2020.04.002 \|2 doi
035			\|a (DE-627)DOAJ065304969
035			\|a (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Harshad Kapare \|e verfasserin \|4 aut
245	1	0	\|a Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties
650		4	\|a plumbagin
650		4	\|a poly (ε-caprolactone)
650		4	\|a design of experiment
650		4	\|a sulforhodamine b (srb) assay
650		4	\|a nanoparticles
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Sarika Metkar \|e verfasserin \|4 aut
700	0		\|a Satish Shirolkar \|e verfasserin \|4 aut
773	0	8	\|i In \|t Nanomedicine Research Journal \|d Iranian Society of Nanomedicine, 2018 \|g 5(2020), 4, Seite 316-323 \|w (DE-627)863980406 \|w (DE-600)2863538-3 \|x 24767123 \|7 nnns
773	1	8	\|g volume:5 \|g year:2020 \|g number:4 \|g pages:316-323
856	4	0	\|u https://doi.org/10.22034/nmrj.2020.04.002 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 \|z kostenfrei
856	4	0	\|u http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2476-3489 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2476-7123 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 5 \|j 2020 \|e 4 \|h 316-323

Indexfelder

author_variant	h k hk s m sm s s ss
matchkey_str	article:24767123:2020----::einndvlpetflmailaeplcpoatnnnprils
hierarchy_sort_str	2020
publishDate	2020
allfields	10.22034/nmrj.2020.04.002 doi (DE-627)DOAJ065304969 (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31 DE-627 ger DE-627 rakwb eng Harshad Kapare verfasserin aut Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles Medicine R Sarika Metkar verfasserin aut Satish Shirolkar verfasserin aut In Nanomedicine Research Journal Iranian Society of Nanomedicine, 2018 5(2020), 4, Seite 316-323 (DE-627)863980406 (DE-600)2863538-3 24767123 nnns volume:5 year:2020 number:4 pages:316-323 https://doi.org/10.22034/nmrj.2020.04.002 kostenfrei https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 kostenfrei http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf kostenfrei https://doaj.org/toc/2476-3489 Journal toc kostenfrei https://doaj.org/toc/2476-7123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 4 316-323
spelling	10.22034/nmrj.2020.04.002 doi (DE-627)DOAJ065304969 (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31 DE-627 ger DE-627 rakwb eng Harshad Kapare verfasserin aut Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles Medicine R Sarika Metkar verfasserin aut Satish Shirolkar verfasserin aut In Nanomedicine Research Journal Iranian Society of Nanomedicine, 2018 5(2020), 4, Seite 316-323 (DE-627)863980406 (DE-600)2863538-3 24767123 nnns volume:5 year:2020 number:4 pages:316-323 https://doi.org/10.22034/nmrj.2020.04.002 kostenfrei https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 kostenfrei http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf kostenfrei https://doaj.org/toc/2476-3489 Journal toc kostenfrei https://doaj.org/toc/2476-7123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 4 316-323
allfields_unstemmed	10.22034/nmrj.2020.04.002 doi (DE-627)DOAJ065304969 (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31 DE-627 ger DE-627 rakwb eng Harshad Kapare verfasserin aut Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles Medicine R Sarika Metkar verfasserin aut Satish Shirolkar verfasserin aut In Nanomedicine Research Journal Iranian Society of Nanomedicine, 2018 5(2020), 4, Seite 316-323 (DE-627)863980406 (DE-600)2863538-3 24767123 nnns volume:5 year:2020 number:4 pages:316-323 https://doi.org/10.22034/nmrj.2020.04.002 kostenfrei https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 kostenfrei http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf kostenfrei https://doaj.org/toc/2476-3489 Journal toc kostenfrei https://doaj.org/toc/2476-7123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 4 316-323
allfieldsGer	10.22034/nmrj.2020.04.002 doi (DE-627)DOAJ065304969 (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31 DE-627 ger DE-627 rakwb eng Harshad Kapare verfasserin aut Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles Medicine R Sarika Metkar verfasserin aut Satish Shirolkar verfasserin aut In Nanomedicine Research Journal Iranian Society of Nanomedicine, 2018 5(2020), 4, Seite 316-323 (DE-627)863980406 (DE-600)2863538-3 24767123 nnns volume:5 year:2020 number:4 pages:316-323 https://doi.org/10.22034/nmrj.2020.04.002 kostenfrei https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 kostenfrei http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf kostenfrei https://doaj.org/toc/2476-3489 Journal toc kostenfrei https://doaj.org/toc/2476-7123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 4 316-323
allfieldsSound	10.22034/nmrj.2020.04.002 doi (DE-627)DOAJ065304969 (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31 DE-627 ger DE-627 rakwb eng Harshad Kapare verfasserin aut Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles Medicine R Sarika Metkar verfasserin aut Satish Shirolkar verfasserin aut In Nanomedicine Research Journal Iranian Society of Nanomedicine, 2018 5(2020), 4, Seite 316-323 (DE-627)863980406 (DE-600)2863538-3 24767123 nnns volume:5 year:2020 number:4 pages:316-323 https://doi.org/10.22034/nmrj.2020.04.002 kostenfrei https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 kostenfrei http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf kostenfrei https://doaj.org/toc/2476-3489 Journal toc kostenfrei https://doaj.org/toc/2476-7123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 4 316-323
language	English
source	In Nanomedicine Research Journal 5(2020), 4, Seite 316-323 volume:5 year:2020 number:4 pages:316-323
sourceStr	In Nanomedicine Research Journal 5(2020), 4, Seite 316-323 volume:5 year:2020 number:4 pages:316-323
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles Medicine R
isfreeaccess_bool	true
container_title	Nanomedicine Research Journal
authorswithroles_txt_mv	Harshad Kapare @@aut@@ Sarika Metkar @@aut@@ Satish Shirolkar @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	863980406
id	DOAJ065304969
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ065304969</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502132337.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.22034/nmrj.2020.04.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065304969</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Harshad Kapare</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">plumbagin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">poly (ε-caprolactone)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">design of experiment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sulforhodamine b (srb) assay</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarika Metkar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satish Shirolkar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nanomedicine Research Journal</subfield><subfield code="d">Iranian Society of Nanomedicine, 2018</subfield><subfield code="g">5(2020), 4, Seite 316-323</subfield><subfield code="w">(DE-627)863980406</subfield><subfield code="w">(DE-600)2863538-3</subfield><subfield code="x">24767123</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:316-323</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.22034/nmrj.2020.04.002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2476-3489</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2476-7123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2020</subfield><subfield code="e">4</subfield><subfield code="h">316-323</subfield></datafield></record></collection>
author	Harshad Kapare
spellingShingle	Harshad Kapare misc plumbagin misc poly (ε-caprolactone) misc design of experiment misc sulforhodamine b (srb) assay misc nanoparticles misc Medicine misc R Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
authorStr	Harshad Kapare
ppnlink_with_tag_str_mv	@@773@@(DE-627)863980406
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	24767123
topic_title	Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity plumbagin poly (ε-caprolactone) design of experiment sulforhodamine b (srb) assay nanoparticles
topic	misc plumbagin misc poly (ε-caprolactone) misc design of experiment misc sulforhodamine b (srb) assay misc nanoparticles misc Medicine misc R
topic_unstemmed	misc plumbagin misc poly (ε-caprolactone) misc design of experiment misc sulforhodamine b (srb) assay misc nanoparticles misc Medicine misc R
topic_browse	misc plumbagin misc poly (ε-caprolactone) misc design of experiment misc sulforhodamine b (srb) assay misc nanoparticles misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Nanomedicine Research Journal
hierarchy_parent_id	863980406
hierarchy_top_title	Nanomedicine Research Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)863980406 (DE-600)2863538-3
title	Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
ctrlnum	(DE-627)DOAJ065304969 (DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31
title_full	Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
author_sort	Harshad Kapare
journal	Nanomedicine Research Journal
journalStr	Nanomedicine Research Journal
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	316
author_browse	Harshad Kapare Sarika Metkar Satish Shirolkar
container_volume	5
format_se	Elektronische Aufsätze
author-letter	Harshad Kapare
doi_str_mv	10.22034/nmrj.2020.04.002
author2-role	verfasserin
title_sort	design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
title_auth	Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
abstract	Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties
abstractGer	Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties
abstract_unstemmed	Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	4
title_short	Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity
url	https://doi.org/10.22034/nmrj.2020.04.002 https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31 http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf https://doaj.org/toc/2476-3489 https://doaj.org/toc/2476-7123
remote_bool	true
author2	Sarika Metkar Satish Shirolkar
author2Str	Sarika Metkar Satish Shirolkar
ppnlink	863980406
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.22034/nmrj.2020.04.002
up_date	2024-07-03T14:04:18.522Z
_version_	1803566929444601856
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ065304969</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502132337.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.22034/nmrj.2020.04.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065304969</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJba534eb14eb84e9b86bd67ab302dfd31</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Harshad Kapare</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly (ε -caprolactone) nanoparticles were investigated as an injectable nanocarrier for the delivery of natural anticancer naphthoquinones plumbagin with the primary aim of improvement in its solubility, drug release profile and in vitro cytotoxicity. Plumbagin loaded polymeric nanoparticle system was fabricated by nanoprecipitation method and the composition was optimized using factorial design approach. Nanoparticles showed particle size and encapsulation efficiency of 186 ± 1 - 300 ± 3 nm and 65.00+ 1.50- 74.00+ 1.80% respectively. Optimization was carried out and optimized formulation showed sustained drug release over a period of 24 h. Total growth inhibition of cells in a designed time period (TGI) concentration was decreased by 56.95 % for PNP as compared to Plumbagin in human breast cancer MCF-7 cells indicates improved cytotoxicity of Plumbagin. The formulation development study proven that the developed PNP system exhibited improved solubility, sustained drug release, enhanced in vitro cytotoxicity in MCF-7 cell lines in comparison with Plumbagin. Thus the designed formulation approach can be further developed as novel carrier for plumbagin to enhance its biopharmaceutical properties</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">plumbagin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">poly (ε-caprolactone)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">design of experiment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sulforhodamine b (srb) assay</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarika Metkar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satish Shirolkar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nanomedicine Research Journal</subfield><subfield code="d">Iranian Society of Nanomedicine, 2018</subfield><subfield code="g">5(2020), 4, Seite 316-323</subfield><subfield code="w">(DE-627)863980406</subfield><subfield code="w">(DE-600)2863538-3</subfield><subfield code="x">24767123</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:316-323</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.22034/nmrj.2020.04.002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ba534eb14eb84e9b86bd67ab302dfd31</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.nanomedicine-rj.com/article_47984_8696a686f3306c0100203214b464f880.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2476-3489</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2476-7123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2020</subfield><subfield code="e">4</subfield><subfield code="h">316-323</subfield></datafield></record></collection>
score	7.400528

Nicht das Richtige dabei?

Schreiben Sie uns!

Design and development of plumbagin loaded poly (ε -caprolactone) nanoparticles for improved cytotoxicity

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?